FDA Approval Status Update for Bosentan ANDA207760 by Zydus Pharmaceuticals
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of 'AP' for Bosentan submitted by Zydus Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Bosentan with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Endothelin Receptor Antagonist
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.